Related Experiment Video
Updated: May 16, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
[Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review]
Hui Lin Peng1,2, Hai Yan Yang1,2
1Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, Zhejiang Province, China.
Abstract:
Plasmablastic lymphoma (PL/PBL) is a rare type of lymphoma with strong aggressive ability and poor prognosis. Currently,there is a lack of strict diagnostic and therapeutic criteria. In addition to traditional plasma cell markers, SLAMF7 may be a useful adjunct to diagnostic markers for PBL. High-dose chemotherapy combined with bortezomib or lenalidomide may be a promising first-line option for PBL. In second-line therapy, novel therapies such as immune checkpoint inhibitors, CAR-T, and novel targeted agents appear to further improve the survival of patients with PBL. This article mainly reviews the diagnosis, differentiation, first-line treatment of PBL, and treatment of relapsed/refractory PBL, so as to further explore this disease.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tumor Immunotherapy

